Chronic pruritus in primary Sjögren syndrome: Characteristics and effect on quality of life

2016 ◽  
Vol 74 (5) ◽  
pp. AB79
2015 ◽  
Vol 42 (8) ◽  
pp. 1427-1431 ◽  
Author(s):  
Roberta Priori ◽  
Antonina Minniti ◽  
Martina Derme ◽  
Barbara Antonazzo ◽  
Filippo Brancatisano ◽  
...  

Objective.To assess the quality of sexual life of women with primary Sjögren syndrome (pSS) and to identify its correlations with disease activity and damage, quality of life, and mood disorders.Methods.The quality of sexual life of 24 women with pSS was assessed with the Female Sexual Function Index (FSFI). Twenty-four healthy women, matched by age and hormonal status, were enrolled as controls. Mood disorders and quality of life were investigated using the Hospital Anxiety and Depression Scale (HADS) and the Medical Outcomes Study Short Form-36. Patients underwent a gynecological visit with vaginal pH measurement, cervicovaginal swabs, and Pap smears. Disease activity and damage were assessed by the European League Against Rheumatism Sjögren syndrome disease activity and damage indexes.Results.Patients with pSS showed a pathological mean FSFI score (19.1 ± 7.33) significantly different from controls (p = 0.004), both in menstruating women (p = 0.006) and in menopausal women (p = 0.03). Major differences between the 2 groups were detected in dyspareunia (p < 0.005), lubrication (p = 0.006), desire (p = 0.004), and arousal (p = 0.018). The FSFI score was inversely correlated with age (p = 0.008) and anxiety HADS (p = 0.031). No early anatomical changes, swabs, and Pap smear alterations were revealed in patients with pSS; however, vaginal pH was higher than normal in premenopausal patients (6.0 ± 0.77).Conclusion.Both premenopausal and postmenopausal women with pSS have a worse sexual quality of life. We reported a greater prevalence of dyspareunia that is statistically significant when compared with controls. The FSFI could be a useful tool to assess this topic, but has been neglected in the care of patients with pSS heretofore.


2021 ◽  
Author(s):  
Ana Paula Truhlar Pedrini ◽  
Bianca Domingos Noronha ◽  
Pedro Henrique Alves dos Santos ◽  
Letícia Fonseca Favarato ◽  
Luíza Vallory Alochio ◽  
...  

2008 ◽  
Vol 139 (3) ◽  
pp. 291-299 ◽  
Author(s):  
Carol M. Stewart ◽  
Kathleen M. Berg ◽  
Seunghee Cha ◽  
Westley H. Reeves

2021 ◽  
Vol 182 ◽  
pp. 106405
Author(s):  
Santiago Auteri ◽  
María L. Alberti ◽  
Martin E. Fernández ◽  
Guadalupe Blanco ◽  
Mercedes Rayá ◽  
...  

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Simon Parreau ◽  
Jérémie Jacques ◽  
Stéphanie Dumonteil ◽  
Sylvain. Palat ◽  
Sophie Geyl ◽  
...  

Abstract Background Abdominal symptoms in patients with primary Sjögren syndrome (pSS) are poorly documented. The objective of the study was to describe the abdominal symptoms of patients with pSS and to assess their association with characteristics of the disease. Methods One hundred and fifty patients with pSS were evaluated using a composite global symptom score for abdominal symptoms and their severity. Data concerning the clinical and biological characteristics of pSS and abdominal disorders were also collected. Results Of the patients with pSS, 95% suffered from abdominal symptoms (median global symptom score 7.5 ± 5.5 points out of 30). More than half of the patients experienced abdominal tension (68%), upper abdominal pain (54%), abdominal discomfort (58%) and/or constipation (54%). Regarding the pSS activity, in relation to European League Against Rheumatism (EULAR) Sjögren syndrome disease activity index score items, general and central nervous system involvement wereassociated with a high global symptom score. The EULAR Sjogren Syndrome Patient Reported Index (ESSPRI) symptom score was positively correlated with the global symptom score (p < 0.01). Multivariate analysis showed a significant association between a high global symptom score and SSA seronegativity, gastroparesis, and ESSPRI score (p < 0.01 for each). Conclusions The majority of patients with pSS suffered abdominal symptoms. There is currently no therapeutic recommendation because of the lack of information on the underlying pathophysiological mechanisms. Trial registration NCT03157011. Date of registration: July 17, 2017.


Sign in / Sign up

Export Citation Format

Share Document